Head-to-Head

Atossa Therapeutics, Inc. Common Stock vs. Eli Lilly & Co.

ATOS

Atossa Therapeutics, Inc. Common Stock

$2.45 +2.08%

VS LLY

Eli Lilly & Co.

$1170.14 +0.45%

Eli Lilly & Co. (LLY) comes out ahead, leading on 5 of 6 compared factors.

Size & Scale

ATOSLLY
Market Cap $23.95 million $1.04 trillion
Revenue (TTM) — $79.67 billion
Net Income (TTM) $-37,709,000 $26.71 billion

LLY leads on 3 of 3 size & scale factors.

Valuation

ATOSLLY
P/E Ratio — 39.28
Price / Book 0.89 30.65
Price / Sales — 13.03

ATOS leads on 1 of 1 valuation factors.

Profitability

ATOSLLY
Net Margin — 33.53%
Return on Equity -140.55% 78.84%

LLY leads on 1 of 1 profitability factors.

Dividend

ATOSLLY
Dividend Yield — 0.59%
Payout Ratio — 23.23

ATOS and LLY split the dividend factors evenly.

Risk & Sentiment

ATOSLLY
Short Interest 15.54% 1.29%

LLY leads on 1 of 1 risk & sentiment factors.

Dig deeper: ATOS overview, ATOS financials, LLY overview, LLY financials.

Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.